Obesity May Increase End-Stage Kidney Disease Risk in Women with Type 2 Diabetes

Obesity may negatively affect kidney function in people with type 2 diabetes, particularly in women, according to a new study published in the Endocrine Society’s Journal of Clinical Endocrinology & Metabolism.

Diabetic nephropathy, or the deterioration of kidney function in people with diabetes, is caused by high blood pressure and high blood sugar. Approximately one in three adults with diabetes has chronic kidney disease, and kidney diseases are the ninth leading cause of death in the United States. Kidney disease progresses over time to end-stage renal disease, and people with end-stage kidney disease often need a kidney transplant to stay alive.

“Our research highlights how obesity contributes to the incidence and progression of diabetic nephropathy in people with type 2 diabetes, especially for women,” says Zhi-Hong Liu, MD, of Jinling Hospital and Nanjing University School of Medicine in Nanjing, China “Managing your blood pressure and blood sugar may not be enough to slow the progression to end stage renal disease, and our study shows how important it is for people with diabetes to also manage their weight.”

The researchers analyzed body mass index data from 158,284 East Asian adults from the BioBank Japan Project. Genetic evidence showed that higher body mass index levels were associated with an increased risk of diabetic kidney disease and decreased kidney filtration rate levels in 3,972 people with type 2 diabetes. Body mass index was not causally associated with increased levels of protein in the urine. Women with obesity and type 2 diabetes had a greater risk of diabetic kidney disease than men.

“People with diabetes and obesity should have their kidneys checked more often as they are at high risk, and while chronic kidney disease has no cure, early detection and obesity treatment could slow the progression to end-stage kidney disease,” Liu says.

Other authors of the study include: Jingru Lu of Jinling Hospital and Nanjing University School of Medicine; Xiaoshuang Liu and Xiang Li of Ping An Healthcare Technology in Beijing, China; Song Jiang, Shuyan Kan, Yu An and Chunxia Zheng of Jinling Hospital; and Guotong Xie of Ping An Healthcare Technology, Ping An Health Cloud Company Limited and Ping An International Smart City Technology Co., Ltd in Beijing, China.

The study received funding from the National Key Research and Development Program and the Key R&D Projects of Jiangsu Province.

The manuscript, “Body Mass Index and Risk of Diabetic Nephropathy: A Mendelian Randomization Study,” was published online, ahead of print.

You may also like

  • Two Medication Classes Reduced Cardiovascular and Liver Events in People with Type 2 Diabetes

    GLP-1 receptor agonists (GLP-1s) and SGLT-2 inhibitors lower the risk of major cardiovascular events like heart attacks and severe liver complications compared to other diabetes treatments, according to data presented at ENDO 2024. Researchers reviewed Medicare data documented from 2013 to 2020 and a large U.S. health insurance database from 2013 to 2022. They performed…

  • Liraglutide Increases Insulin Sensitivity Independent of Weight Loss, Study Shows

    Liraglutide, the glucagon-like peptide-1 receptor (GLP-1R) agonist used to treat type 2 diabetes and obesity, can lead to rapid improvement in insulin sensitivity, according to a study recently published in Diabetes. “We know that GLP-1R agonists promote weight loss, but we were surprised to find that the GLP-1R agonist liraglutide also has rapid effects on…

Find more in